Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$0 Mln
P/E Ratio
--
P/B Ratio
3.33
Industry P/E
--
Debt to Equity
0
ROE
-1.2 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-39.21 Mln
EBITDA
$-47.55 Mln
Net Profit
$-48.67 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Virios Therapeutics (VIRI)
| -80.94 | -36.28 | -39.45 | -83.88 | -71.31 | -- | -- |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
|
|---|---|---|---|
|
Virios Therapeutics (VIRI)
| 143.64 | -95.39 | -31.89 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 59.98 | 2,341.96 | -- | -25.93 | |
| 4.34 | 37.54 | -- | -312.41 | |
| 13.26 | 21.14 | -- | -83.45 |
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1,... a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. Read more
Chairman & CEO
Mr. Gregory Duncan
Chairman & CEO
Mr. Gregory Duncan
Headquarters
Alpharetta, GA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Virios Therapeutics Inc (VIRI) stood at $ 4 Mln as on 30-Jun-24
The share price of Virios Therapeutics Inc (VIRI) is $2.74 (NASDAQ) as of 10-Dec-2024 09:30 EDT. Virios Therapeutics Inc (VIRI) has given a return of -71.31% in the last 3 years.
Virios Therapeutics Inc (VIRI) has a market capitalisation of $ 0 Mln as on 10-Dec-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Virios Therapeutics Inc (VIRI) is 3.33 times as on 10-Dec-2024, a 47% premium to its peers’ median range of 2.26 times.
Since, TTM earnings of Virios Therapeutics Inc (VIRI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Virios Therapeutics Inc (VIRI) and enter the required number of quantities and click on buy to purchase the shares of Virios Therapeutics Inc (VIRI).
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
The CEO & director of Mr. Gregory Duncan. is Virios Therapeutics Inc (VIRI), and CFO & Sr. VP is Mr. Gregory Duncan.
There is no promoter pledging in Virios Therapeutics Inc (VIRI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
234
|
|
|
4
|
|
|
2
|
|
|
234
|
| Virios Therapeutics Inc. (VIRI) | Ratios |
|---|---|
|
Return on equity(%)
|
-134.8
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Virios Therapeutics Inc (VIRI) was $0 Mln.
$0.37
(
